Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH.
Hsu SJ, et al. Among authors: tsai ch.
J Formos Med Assoc. 2020 Mar;119(3):712-719. doi: 10.1016/j.jfma.2019.10.003. Epub 2019 Oct 28.
J Formos Med Assoc. 2020.
PMID: 31672433
Free article.